WO1988008840A1 - Agents de ciblage antitumoraux, leur preparation et applications - Google Patents
Agents de ciblage antitumoraux, leur preparation et applications Download PDFInfo
- Publication number
- WO1988008840A1 WO1988008840A1 PCT/FR1988/000213 FR8800213W WO8808840A1 WO 1988008840 A1 WO1988008840 A1 WO 1988008840A1 FR 8800213 W FR8800213 W FR 8800213W WO 8808840 A1 WO8808840 A1 WO 8808840A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ppm
- nitro
- imidazole
- compound
- chloroethyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 5
- 230000000259 anti-tumor effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 14
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 13
- 230000008878 coupling Effects 0.000 claims abstract description 5
- 238000010168 coupling process Methods 0.000 claims abstract description 5
- 238000005859 coupling reaction Methods 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 152
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 34
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- -1 benzymidazolyl Chemical group 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 230000003034 chemosensitisation Effects 0.000 claims description 7
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 6
- 229960004961 mechlorethamine Drugs 0.000 claims description 6
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WJSDAFAYDXCQLE-UHFFFAOYSA-N (2,4,5-trichlorophenyl) n-(2-chloroethyl)-n-nitrosocarbamate Chemical group ClCCN(N=O)C(=O)OC1=CC(Cl)=C(Cl)C=C1Cl WJSDAFAYDXCQLE-UHFFFAOYSA-N 0.000 claims 1
- 239000002547 new drug Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 79
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 39
- 239000000460 chlorine Substances 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 39
- 239000000377 silicon dioxide Substances 0.000 description 37
- 239000003480 eluent Substances 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 21
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 17
- 206010021143 Hypoxia Diseases 0.000 description 16
- 230000001146 hypoxic effect Effects 0.000 description 16
- 238000010586 diagram Methods 0.000 description 11
- VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000004593 Epoxy Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000002460 imidazoles Chemical class 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- DAJARBUJEJVGDQ-UHFFFAOYSA-N (4-nitrophenyl) n-(2-chloroethyl)-n-nitrosocarbamate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)N(CCCl)N=O)C=C1 DAJARBUJEJVGDQ-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- DUILGEYLVHGSEE-UHFFFAOYSA-N 2-(oxiran-2-ylmethyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1CO1 DUILGEYLVHGSEE-UHFFFAOYSA-N 0.000 description 3
- FFYTTYVSDVWNMY-UHFFFAOYSA-N 2-Methyl-5-nitroimidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1 FFYTTYVSDVWNMY-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- UKYAPGRNQNGWQK-UHFFFAOYSA-N phenyl n-(2-chloroethyl)-n-nitrosocarbamate Chemical compound ClCCN(N=O)C(=O)OC1=CC=CC=C1 UKYAPGRNQNGWQK-UHFFFAOYSA-N 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- IAOGWYABFHUNKI-UHFFFAOYSA-N 1h-imidazole;dihydrochloride Chemical compound Cl.[Cl-].C1=C[NH+]=CN1 IAOGWYABFHUNKI-UHFFFAOYSA-N 0.000 description 2
- 150000004959 2-nitroimidazoles Chemical class 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- JOCIMPQRWDNKIC-UHFFFAOYSA-N C1=CN(C(=N1)CCCl)[N+](=O)[O-] Chemical class C1=CN(C(=N1)CCCl)[N+](=O)[O-] JOCIMPQRWDNKIC-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 150000004957 nitroimidazoles Chemical class 0.000 description 2
- 230000000247 oncostatic effect Effects 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 125000005543 phthalimide group Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- CYJBWQFWXJKKMS-UHFFFAOYSA-N 1-amino-3-chloropropan-2-ol Chemical compound NCC(O)CCl CYJBWQFWXJKKMS-UHFFFAOYSA-N 0.000 description 1
- IWDUDCDZGOLTTJ-UHFFFAOYSA-N 1h-imidazole;silver Chemical compound [Ag].C1=CNC=N1 IWDUDCDZGOLTTJ-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- CHZXTOCAICMPQR-UHFFFAOYSA-N 2-(2-bromoethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCBr)C(=O)C2=C1 CHZXTOCAICMPQR-UHFFFAOYSA-N 0.000 description 1
- HOCPDSKONPQIQM-UHFFFAOYSA-N 4-(2-bromoethyl)isoindole-1,3-dione Chemical compound BrCCC1=CC=CC2=C1C(=O)NC2=O HOCPDSKONPQIQM-UHFFFAOYSA-N 0.000 description 1
- LLUAYKBVIKUBSD-UHFFFAOYSA-N 5-nitro-1H-imidazole dihydrochloride Chemical compound Cl.Cl.[O-][N+](=O)c1cnc[nH]1 LLUAYKBVIKUBSD-UHFFFAOYSA-N 0.000 description 1
- FUHUQBSNHRFQFQ-UHFFFAOYSA-N 5-nitro-1H-imidazole hydrochloride Chemical compound Cl.[O-][N+](=O)C1=CN=CN1 FUHUQBSNHRFQFQ-UHFFFAOYSA-N 0.000 description 1
- 150000004958 5-nitroimidazoles Chemical class 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N Cyclohexane Natural products CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- JILGJCGLYLCARC-UHFFFAOYSA-N NCCC=1N(C=CN=1)[N+](=O)[O-] Chemical compound NCCC=1N(C=CN=1)[N+](=O)[O-] JILGJCGLYLCARC-UHFFFAOYSA-N 0.000 description 1
- MXRLMQDRNFNSKK-UHFFFAOYSA-N [N+](=O)([O-])C=1NC=C(N=1)C=1C2C(C(=O)NC2=O)(C=CC=1)CC Chemical compound [N+](=O)([O-])C=1NC=C(N=1)C=1C2C(C(=O)NC2=O)(C=CC=1)CC MXRLMQDRNFNSKK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006114 chemosensitizer Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
- 229950010514 misonidazole Drugs 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/95—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by nitrogen atoms, attached to other ring members
Definitions
- Anti-tumor targeting agents their preparation and applications
- the present invention relates to new compounds which result from the coupling of a molecule having a chemosensitizing structure and a molecule having a cytotoxic structure, their preparation process, as well as their application as medicaments.
- a molecule having a chemosensitizing structure and a molecule having a cytotoxic structure
- their preparation process as well as their application as medicaments.
- Another problem is that caused by solid tumors; the hypoxic cells present in these tumors show therapeutic resistance to most anti-cancer agents.
- the resistance mechanism of these cells is quite complex and involves kinetic, metabolic and physical factors.
- these cells are known to be placed at a distance from blood vessels, which prevents certain drugs from diffusing to the desired location.
- Radiosensitizers have already been proposed having an affinity for hypoxic cells, teksquele Misonidazole.
- the present invention aims to overcome the drawbacks listed above by providing new compounds which result from the coupling of a molecule having a chemosensitizing structure and a molecule having a cytotoxic structure. These compounds will make it possible to chemosensitize hypoxic tumor cells and to specifically deliver to them a cytotoxic entity interacting on their DNA.
- the molecule having a cytotoxic structure is, more preferably, derived from an alkylating cytotoxic molecule. It can be a molecule derived from a nitrosourea or a nitrogen mustard.
- the molecule having a chemosensitizing structure will, preferably, be derived from a molecule with an aromatic cycle, or pseudo-aromatio
- the compounds of the present invention correspond to farmule I in which X is a residue of a benzene ring or of a heterocycle comprising nitrogen as the heteroatom of formula XH in which H represents hydrogen, X being substituted by at least one group -NO 2 , R 1 is H, or SH and R 2 is a group derived from nitrosourea or nitrogen mustard.
- X is chosen from the following radicals: benzyl, triazolyl, benzymidazolyl, imidazolyl, tetrazolyl.
- R 2 is -NH-CO-N (NO) -CH 2 -CH 2 -Cl provided that R 1 is a hydrogen atom, or R 2 is CH 2 -NH- CO-N (NO) -CH 2 -CH 2 Cl, provided that R 1 is OH or SH.
- Particularly preferred compounds are the following: [[(2-chloro-ethyl) -3 3-nitroso-ureido] -3-2-hydroxypropyl] -1 4-nitro imidazole, [[(2-chloro-ethyl) -3 nitroso-3 ureido] -3 hydroxy-2 propyl] -1 nitro-5 imidazole,
- R 2 is NH-CH 2 -CH 2 - Cl or N (CH 2 -CH 2 -Cl) 2 or NH-C 6 H 4 -N (CH 2 CH 2 Cl) 2 provided that R 1 is a hydrogen atom or R 2 is CH 2 -NH- CH 2 -CH 2 -Cl or CH 2 -N (CH 2 CH 2 Cl) 2 or CH 2 -NH-C 6 H 4 -N (CH 2 CH 2 Cl) 2 provided that R 1 is OH or SH.
- Particularly preferred compounds are the following:
- the present invention also relates to a process for the preparation of compounds of formula I.
- R 2 is a nitrosourea
- R 2 -NH-CO-N (CO) -N (NO) -CH 2 -CH 2 -Cl or
- R NO 2
- R 3 CH 2 CH 2 Cl
- XH H is linked to the heteroatom when X represents a heterocycle comprising nitrogen as the heteroatom.
- -R 6 , -R 7 chosen from in particular H, CH 2 -CH 2 OH and
- the invention therefore provides molecules aiming to chemosensitize hypoxic tumor cells and to specifically deliver to them a cytotoxic entity which inter-reacts with their DNA.
- the compounds of the present invention are useful as medicaments.
- the present invention therefore therefore also relates to the application of the compounds as medicaments as well as pharmaceutical compositions comprising, in addition to a pharmaceutically acceptable carrier, an active principle comprising at least one compound as described above.
- an active principle comprising at least one compound as described above.
- - Figure 1 represents, for certain compounds of the present invention, the evolution of the number of surviving cells of a Mer- line as a function of the quantity administered ( ⁇ moles)
- - Figure 2 represents, for certain compounds of the present invention, the evolution of the number of surviving cells of a Mer + line as a function of the quantity administered (in ⁇ moles).
- nitrosoureas of the A and B series were synthesized by coupling between the amine and an active ester comprising the N- (2-chloroethyl) N-nitrosocarbamate unit according to the " active esters "used in peptide synthesis (Diagram 1)).
- the alkanolamines were synthesized by treatment of (epoxyalkyl) -1 nitro-2 imidazoles with a number of secondary and primary amines. By this method of synthesis secondary and tertiary amines are obtained.
- the primary alkanolamines are prepared by the reaction of ammonia with the epoxides.
- 1 '(2-aminoethyl) -1 2-nitro imidazole can be obtained by the action of aziridine on 2-nitro imidazole.
- Nitroimidazoles (hydroxyaminoalkyl) -1 are obtained via nitro-imidazole intermediates N- (hydroxyalkyl) phthalimides.
- R H 19 28 (71%)
- R nltro-4 20 29 (89%)
- R nitro-3 21 30 (67%)
- R nitro-2 23 37 (81%)
- the oil bath is brought to 100 ° C for 10 minutes.
- the solution is then brought to room temperature; 12 ml (155 mmol) of 1,2-dichloroethane are then added.
- the duration of the addition is 1 hour.
- reaction mixture is then evaporated under vacuum; the oily residue is thrown into a mixture of 200 ml of ice water. Neutralized with ammonia and extracted 5 times with 50 ml of toluene then 3 times with 30 ml of dichloromethane.
- This compound was prepared in a manner analogous to Example 3 of compound 14 with a yield of 60%.
- This compound was prepared in a manner analogous to Example 12 from compound No. 7 with a yield of 69%.
- This compound was prepared in a manner analogous to Example 12 from the non-MS compound with a yield of 70%.
- This compound was prepared in a manner analogous to Example 20 from compound No. 16 with a yield of 72%.
- This compound was prepared in a manner analogous to Example 20 from compound No. 17 with a yield of 56%.
- This compound was prepared in a manner analogous to Example 20 from compound 20 with a yield of 69%.
- This compound was prepared in a manner analogous to Example 20 from compound No. 21 with a yield of 67%.
- This compound was prepared in a manner analogous to Example 28 from commercial nitro-4 (5) imidazole. The yield obtained is 71%.
- R H, Nitro-4, Nitro-5, Nitro-2.
- the difference between these two types of cells is the presence or absence of a separating enzyme, 0-6 methyltransferase.
- BME Eagle base medium
- the cells used in an aerobic environment are suspended in 10 ml of Eagle base medium (BME) at a concentration of 1 to 2.10 per milliliter, and placed in a type I treatment flask as described by Whilliams and Rauth.
- BME Eagle base medium
- the cells are added to the vials containing the BME only after the medium has remained in a gaseous mixture 97% N 2 /3% CO 2 for 3 hours.
- the cells are incubated for 10 minutes at a concentration of 2 ⁇ 10 7 cells / ml in a Hamilton syringe
- the relative aerobic and hypoxic toxicity of the various compounds was calculated using the DEF factor defined as the ratio of the amounts required to reduce the surviving cells to 0.01, respectively, under aerobic and hypoxic conditions.
- Figures 1 and 2 illustrate the results obtained and give the percentage of surviving cells as a function of the dose of compound administered (in ⁇ mol).
- N2 represents the hypoxic medium while O2 represents the aerobic medium.
- Figure 1 expresses more precisely the results obtained with Mer- cells while Figure 2 expresses the results obtained with Mer + cells.
- the compounds tested are cytotoxic with respect to Mer- cells (Hela-MR), both under aerobic and hypoxic conditions, except for the non-nitrated imidazole derivatives I-273 (no24) and 1-283 (no. 28).
- the Mer + cells (Hela - 53) are, as should be expected, more resistant to the products tested. All the compounds of the A series are less toxic than those of the B series.
- the compounds I-278 and I-282 (31 and 27) once again exhibit increased cytotoxicity under conditions hypoxic (DEF close to 1.3).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR87/06241 | 1987-05-04 | ||
FR8706241A FR2614890B1 (fr) | 1987-05-04 | 1987-05-04 | Compose resultant du couplage d'une molecule a structure chimiosensibilisante et d'une molecule a structure cytotoxique, procede de preparation, application a titre de medicament et compositions pharmaceutiques le contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1988008840A1 true WO1988008840A1 (fr) | 1988-11-17 |
Family
ID=9350728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1988/000213 WO1988008840A1 (fr) | 1987-05-04 | 1988-05-03 | Agents de ciblage antitumoraux, leur preparation et applications |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0358684A1 (fr) |
FR (1) | FR2614890B1 (fr) |
WO (1) | WO1988008840A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0700376A1 (fr) * | 1993-05-25 | 1996-03-13 | Auckland Uniservices Limited | Sels quarternaires de moutarde au nitrobenzile et leur utilisation en tant qu'agents cytotoxiques agissant selectivement contre l'hypoxie |
EP1043316A2 (fr) * | 1999-04-08 | 2000-10-11 | S & H Pharm Technology Co. Ltd | Dérivés de nitroimidazole en tant que renforceur de sensibilité pour la chémothérapie et la radiothérapie |
US20080085237A1 (en) * | 2006-10-06 | 2008-04-10 | Raleigh James A | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia |
WO2022210189A1 (fr) * | 2021-03-30 | 2022-10-06 | ナミックス株式会社 | Catalyseur de durcissement, composition de résine, matériau d'étanchéité, adhésif, et produit durci |
WO2022210190A1 (fr) * | 2021-03-30 | 2022-10-06 | ナミックス株式会社 | Dérivé d'amine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2540491A1 (fr) * | 1983-02-08 | 1984-08-10 | Centre Nat Rech Scient | Nouvelles nitrosourees, leur procede de preparation et leur application therapeutique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58188892A (ja) * | 1982-04-26 | 1983-11-04 | Tetsuo Suami | 新規なニトロソウレア化合物 |
-
1987
- 1987-05-04 FR FR8706241A patent/FR2614890B1/fr not_active Expired
-
1988
- 1988-05-03 WO PCT/FR1988/000213 patent/WO1988008840A1/fr not_active Application Discontinuation
- 1988-05-03 EP EP19880904232 patent/EP0358684A1/fr not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2540491A1 (fr) * | 1983-02-08 | 1984-08-10 | Centre Nat Rech Scient | Nouvelles nitrosourees, leur procede de preparation et leur application therapeutique |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0700376A1 (fr) * | 1993-05-25 | 1996-03-13 | Auckland Uniservices Limited | Sels quarternaires de moutarde au nitrobenzile et leur utilisation en tant qu'agents cytotoxiques agissant selectivement contre l'hypoxie |
EP0700376A4 (fr) * | 1993-05-25 | 1996-05-22 | Auckland Uniservices Ltd | Sels quarternaires de moutarde au nitrobenzile et leur utilisation en tant qu'agents cytotoxiques agissant selectivement contre l'hypoxie |
US5872129A (en) * | 1993-05-25 | 1999-02-16 | Auckland Uniservices Limited | Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents |
EP1043316A2 (fr) * | 1999-04-08 | 2000-10-11 | S & H Pharm Technology Co. Ltd | Dérivés de nitroimidazole en tant que renforceur de sensibilité pour la chémothérapie et la radiothérapie |
EP1043316A3 (fr) * | 1999-04-08 | 2000-11-02 | S & H Pharm Technology Co. Ltd | Dérivés de nitroimidazole en tant que renforceur de sensibilité pour la chémothérapie et la radiothérapie |
US20080085237A1 (en) * | 2006-10-06 | 2008-04-10 | Raleigh James A | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia |
JP2010505864A (ja) * | 2006-10-06 | 2010-02-25 | ナチュラル ファーマシア インターナショナル インコーポレイティッド | 組織低酸素症の非侵襲的検出用の弱塩基性2−ニトロイミダゾール |
US9056136B2 (en) | 2006-10-06 | 2015-06-16 | Natural Pharmacia International, Inc. | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia |
WO2022210189A1 (fr) * | 2021-03-30 | 2022-10-06 | ナミックス株式会社 | Catalyseur de durcissement, composition de résine, matériau d'étanchéité, adhésif, et produit durci |
WO2022210190A1 (fr) * | 2021-03-30 | 2022-10-06 | ナミックス株式会社 | Dérivé d'amine |
Also Published As
Publication number | Publication date |
---|---|
FR2614890A1 (fr) | 1988-11-10 |
EP0358684A1 (fr) | 1990-03-21 |
FR2614890B1 (fr) | 1989-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0054951B1 (fr) | Dibenzo(b,f)(1,4)oxazépines, leur procédé de préparation et les compositions pharmaceutiques les contenant | |
EP2024335B1 (fr) | Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament | |
EP0340064B1 (fr) | Benzodiazépines, leur procédé et intermédiaires de préparation et leurs applications en thérapeutique | |
FR2511679A1 (fr) | Nouvelles imidazotetrazinones, leur preparation et les medicaments qui les contiennent | |
EP0073161B1 (fr) | Nouveaux dérivés de la pyrazine actifs sur le système nerveux central | |
EP1355887A1 (fr) | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation | |
EP0226508A1 (fr) | Dérivés de l'indolo(3,2-c)quinoléine, leur procédé de préparation et leur activité antitumorale | |
EP0343050A1 (fr) | Dérivés de phényl-6 pipérazinyl-alkyl-3 1H,3H-pyrimidinedione-2,4, leur préparation et leur application en thérapeutique | |
WO1988008840A1 (fr) | Agents de ciblage antitumoraux, leur preparation et applications | |
FR2499577A1 (fr) | Nouvelles 1-(2-chloroethyl)-1-nitrosourees-3-substituees par un reste de sucre, utiles notamment comme agents antitumoraux et leur procede de preparation | |
FR2631827A1 (fr) | Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique | |
EP0000452B1 (fr) | Dérivés d'oxadiazole-1,2,4, leur préparation et leur application en thérapeutique. | |
BE1003519A3 (fr) | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
EP0021991B1 (fr) | Dérivés de la cystamine, leur préparation et compositions pharmaceutiques les contenant | |
EP0015171A1 (fr) | Dérivés condensés de pyrrolidine ou de pipéridine, leur procédé de préparation et composition les contenant | |
EP0037344A1 (fr) | Amino-alcoxy pyrazoles, procédé pour leur préparation, et médicaments les contenant | |
EP0402227A1 (fr) | Dérivés de phényl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur préparation et leur application en thérapeutique | |
EP0032856A1 (fr) | Nouveaux dérivés de dihydro-2,3-imidazo(1,2-b)pyridazines, leur procédé de préparation et leur application en thérapeutique | |
EP0133096A1 (fr) | Nouveaux dérivés de synergistines, leur préparation et les compositions pharmaceutiques qui les contiennent | |
FR2668152A1 (fr) | Derives n,o spirocycliques de cyclotriphosphazenes, leur preparation et leur application en therapeutique. | |
EP0168288B1 (fr) | Nouveaux dérivés de l'aminométhyl-6 furo-(3,4-c)-pyridine, leur procédé de préparation et compositions thérapeutiques les contenant | |
FR2676733A1 (fr) | Derives de phenyl-1 dihydro-1,4 hydroxy-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique. | |
WO1989012634A1 (fr) | [(aryl-4-piperazinyl-1)-2 ethoxy]-3 p-cymene, les derives ortho, meta, para monosubstitues ou disubstitues sur le noyau phenyle dudit produit, le procede de preparation desdits derives, et les medicaments contenant lesdits composes comme principe actif | |
EP0604301B1 (fr) | Nouveaux dérivés de p-[di(2-chloroéthyl)amino]phénylalanine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
FR2504141A1 (fr) | Nouveaux derives dioxazabicycliques, leur procede de preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988904232 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988904232 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1988904232 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988904232 Country of ref document: EP |